Balance Sheet
Cash Flow Statement
Capital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in IntangiblesChange in ReceivablesDepreciation & Amortization (CF)Depreciation and DepletionFree Cash FlowGains from Investment SecuritiesGains from Sales and DivestituresNet Cash FlowNet IncomeNon-cash ItemsShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Aclaris Therapeutics (ACRS) Non-cash Items (2017 - 2025)

Historic Non-cash Items for Aclaris Therapeutics (ACRS) over the last 9 years, with Q3 2025 value amounting to $12.4 million.

  • Aclaris Therapeutics' Non-cash Items rose 782.61% to $12.4 million in Q3 2025 from the same period last year, while for Sep 2025 it was $12.4 million, marking a year-over-year increase of 782.61%. This contributed to the annual value of $10.0 million for FY2024, which is 7132857.14% up from last year.
  • Per Aclaris Therapeutics' latest filing, its Non-cash Items stood at $12.4 million for Q3 2025, which was up 782.61% from $14.0 million recorded in Q2 2025.
  • In the past 5 years, Aclaris Therapeutics' Non-cash Items ranged from a high of $40.3 million in Q1 2023 and a low of $14000.0 during Q4 2023
  • Over the past 5 years, Aclaris Therapeutics' median Non-cash Items value was $16.6 million (recorded in 2024), while the average stood at $19.8 million.
  • As far as peak fluctuations go, Aclaris Therapeutics' Non-cash Items tumbled by 9990.84% in 2023, and later surged by 7132857.14% in 2024.
  • Quarter analysis of 5 years shows Aclaris Therapeutics' Non-cash Items stood at $13.7 million in 2021, then grew by 11.51% to $15.3 million in 2022, then plummeted by 99.91% to $14000.0 in 2023, then soared by 71328.57% to $10.0 million in 2024, then rose by 24.0% to $12.4 million in 2025.
  • Its last three reported values are $12.4 million in Q3 2025, $14.0 million for Q2 2025, and $14.9 million during Q1 2025.